MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track

MiNK Therapeutics, Inc.

2023-Q1 EPS reported -$0.23

Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.
Cash balance $34.7M at March 31, 2022; projected FY 2022 cash burn $16.8M.
R&D expenses $5.3M (+70% YoY) and G&A $2.1M (+253% YoY) due to increased activity.
Clinical data readouts for agenT-797 in solid tumors and ARDS on track for 2H 2022.
GMP manufacturing launch anticipated in 1H 2022 with target 10,000 doses/yr.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.